tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Prescient Therapeutics Launches $7 Million Share Purchase Plan

Story Highlights
  • Prescient Therapeutics is a clinical stage oncology company developing personalized cancer therapies.
  • The company announced a share purchase plan to raise up to $7 million for advancing clinical programs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Prescient Therapeutics Launches $7 Million Share Purchase Plan

Elevate Your Investing Strategy:

Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.

Prescient Therapeutics Limited has announced a share purchase plan (SPP) aimed at raising up to $7 million, allowing eligible shareholders to purchase shares at $0.04 each. This capital raising initiative is part of the company’s strategy to advance its clinical programs, including the development of PTX-100 and its cell therapy platforms, potentially strengthening its position in the oncology market and offering promising implications for stakeholders.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment. Their primary products include targeted therapies like PTX-100, a unique GGT-1 inhibitor, and cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR, which enhance the effectiveness of adoptive cell therapies and CAR-T cell treatments.

Average Trading Volume: 903,701

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$37.04M

For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1